⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Official Title: Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)

Study ID: NCT02684058

Study Description

Brief Summary: The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high grade glioma (HGG)

Detailed Description: This study combines two pediatric glioma cohorts (LGG and HGG cohorts) into a multi-center, open-label, Phase II study: * The LGG cohort is a multi-center, randomized, open-label part of this Phase II study conducted in children and adolescent patients with BRAF V600 mutation-positive LGG whose tumor was unresectable and who required first systemic treatment. Participants in the LGG cohort were randomized in a 2:1 ratio to either dabrafenib plus trametinib or carboplatin with vincristine. * The HGG cohort is a multi-center, single-arm, open-label part of this Phase II study conducted in children and adolescent patients with BRAF V600 mutation-positive, refractory or relapsed HGG tumors after having received at least one previous standard therapy. The duration of treatment for participants on dabrafenib plus trametinib in LGG and for all patients in the HGG cohort was continued until the loss of clinical benefit in the opinion of the Investigator, unacceptable toxicity, start of a new anti-neoplastic therapy, discontinuation at the discretion of the investigator or patient/legal guardian, lost to follow-up, death, study termination by the sponsor, or until disease progression. The duration of treatment for patients in the carboplatin with vincristine arm in LGG cohort was continued for the prescribed number of cycles, as tolerated or until unacceptable toxicity, start of a new anti-neoplastic therapy, discontinuation at the discretion of the investigator or patient/legal guardian, lost to follow-up, death, study is terminated by the sponsor or until disease progression. Participants randomized to the carboplatin with vincristine treatment arm were allowed to cross over to receive dabrafenib in combination with trametinib after centrally confirmed RANO-defined disease progression. Crossover was allowed during the treatment period or the post-treatment period. After discontinuation of study treatment, all participants (LGG and HGG cohorts) were followed for safety for at least 30 days after the last dose of study treatment. All participants who discontinued study treatment for reasons other than disease progression, death, loss to follow up, or withdrawal of consent moved into the post-treatment efficacy follow-up phase. Finally, all participants were followed for survival once they discontinued study treatment for at least 2 years after the last patient first study treatment (except if consent was withdrawn, death, or the patient was lost to follow-up or discontinued study)

Eligibility

Minimum Age: 12 Months

Eligible Ages: CHILD

Sex: ALL

Healthy Volunteers: No

Locations

Children's Hospital of Orange County, Orange, California, United States

Childrens National Hospital, Washington, District of Columbia, United States

Nicklaus Childrens Hospital, Miami, Florida, United States

Ann and Robert H Lurie Childrens Hospital of Chicago ., Chicago, Illinois, United States

Indiana University School of Medicine ., Indianapolis, Indiana, United States

Johns Hopkins University IDS Pharmacy John Hopkins Hospital, Baltimore, Maryland, United States

Washington University School of Medicine SC, Saint Louis, Missouri, United States

Cincinnati Childrens Hospital Medical Center Cancer & Blood Disease Inst., Cincinnati, Ohio, United States

St Jude Children's Research Hospital, Memphis, Tennessee, United States

Texas Children s Hospital Baylor College of Medicine, Houston, Texas, United States

Novartis Investigative Site, Caba, Buenos Aires, Argentina

Novartis Investigative Site, Randwick, New South Wales, Australia

Novartis Investigative Site, Parkville, Victoria, Australia

Novartis Investigative Site, Brussels, , Belgium

Novartis Investigative Site, Barretos, SP, Brazil

Novartis Investigative Site, Sao Paulo, SP, Brazil

Novartis Investigative Site, Sao Paulo, SP, Brazil

Novartis Investigative Site, Vancouver, British Columbia, Canada

Novartis Investigative Site, Toronto, Ontario, Canada

Novartis Investigative Site, Montreal, Quebec, Canada

Novartis Investigative Site, Brno, , Czechia

Novartis Investigative Site, Praha 5, , Czechia

Novartis Investigative Site, Copenhagen, , Denmark

Novartis Investigative Site, Tampere, , Finland

Novartis Investigative Site, Lille Cedex, , France

Novartis Investigative Site, Lyon, , France

Novartis Investigative Site, Paris, , France

Novartis Investigative Site, Strasbourg, , France

Novartis Investigative Site, Toulouse Cedex, , France

Novartis Investigative Site, Villejuif, , France

Novartis Investigative Site, Augsburg, , Germany

Novartis Investigative Site, Berlin, , Germany

Novartis Investigative Site, Essen, , Germany

Novartis Investigative Site, Gottingen, , Germany

Novartis Investigative Site, Hamburg, , Germany

Novartis Investigative Site, Heidelberg, , Germany

Novartis Investigative Site, Koeln, , Germany

Novartis Investigative Site, Petach-Tikva, , Israel

Novartis Investigative Site, Tel-Hashomer, , Israel

Novartis Investigative Site, Firenze, FI, Italy

Novartis Investigative Site, Genova, GE, Italy

Novartis Investigative Site, Milano, MI, Italy

Novartis Investigative Site, Roma, RM, Italy

Novartis Investigative Site, Torino, TO, Italy

Novartis Investigative Site, Fukuoka city, Fukuoka, Japan

Novartis Investigative Site, Setagaya-ku, Tokyo, Japan

Novartis Investigative Site, Osaka, , Japan

Novartis Investigative Site, Utrecht, CS, Netherlands

Novartis Investigative Site, Moscow, , Russian Federation

Novartis Investigative Site, Barcelona, Catalunya, Spain

Novartis Investigative Site, Madrid, , Spain

Novartis Investigative Site, Valencia, , Spain

Novartis Investigative Site, Stockholm, , Sweden

Novartis Investigative Site, Zuerich, , Switzerland

Novartis Investigative Site, Leeds, , United Kingdom

Novartis Investigative Site, Liverpool, , United Kingdom

Novartis Investigative Site, London, , United Kingdom

Contact Details

Name: Novartis Pharmaceuticals

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: